VRCA - NASDAQ

Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc.

VRCAยทNASDAQ

$6.10

+6.7%
HealthcareBiotechnology

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$64.99M
EPS-1.6800
P/E Ratio-3.63
Earnings Date08/11/2026
Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. Fair Value Envelope

VRCA ยท NASDAQ

Our analysis suggests that VRCA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.101, this represents a potential HIDDEN relative to our calculated worth for Verrica Pharmaceuticals Inc..

HIDDEN
Intrinsic Value
Current Price: $6.101

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$4.7B
+ Cash & Equivalents$30.1M
Firm Value-$4.7B
- Debt$1.6M
Equity Value-$4.7B
/ Shares Outstanding9,490,035B
DCF Value-$493
OVERVALUED BY 8183%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$30.2M
-$51.6M
-$88.3M
-$151.0M
-$258.3M
-$442.0M
-$756.1M
-$1.3B
-$2.2B
-$3.8B
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$30.2M
-$51.6M
-$88.3M
-$151.0M
-$258.3M
-$442.0M
-$756.1M
-$1.3B
-$2.2B
-$3.8B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$27.9M
-$44.2M
-$70.1M
-$111.0M
-$175.8M
-$278.5M
-$441.2M
-$698.9M
-$1.1B
-$1.8B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your VRCA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.